Supplementary Material for: Assessing the clinical and endoscopic efficacy of extended duration treatment with different doses of mesalazine for mild to moderate ulcerative colitis beyond 8 weeks of induction

Introduction: High-strength mesalazine formulations play an important role in providing a convenient option to increase the dose in ulcerative colitis (UC) patients and therefore avoiding the switch to another therapeutic class. Higher doses of mesalazi...